NNNN vs CHEK

Anbio Biotechnology Class A Ordinary Shares (NNNN) offers the better valuation at 475.

0x trailing P/E, making it the more compelling value choice. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Anbio Biotechnology Class A Ordinary Shares (NNNN) delivered a total return of +361.

0%, compared to -92. 9% for Check-Cap Ltd. (CHEK). Over 10 years, the gap is even starker: NNNN returned +361. 0% versus CHEK's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Anbio Biotechnology Class A Ordinary Shares (NNNN) is the lower-risk stock at 0.

58β versus Check-Cap Ltd. 's 0. 67β — meaning CHEK is approximately 16% more volatile than NNNN relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Anbio Biotechnology Class A Ordinary Shares grew EPS 366.

7% year-over-year, compared to -43. 3% for Check-Cap Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Anbio Biotechnology Class A Ordinary Shares (NNNN) is the more profitable company, earning 29.

0% net margin versus 0. 0% for Check-Cap Ltd. — meaning it keeps 29. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NNNN leads at 24. 4% versus 0. 0% for CHEK. At the gross margin level — before operating expenses — NNNN leads at 71. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Anbio Biotechnology Class A Ordinary Shares (NNNN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

58), +361. 0% 10Y return). Both have compounded well over 10 years (NNNN: +361. 0%, CHEK: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NNNN is a small-cap high-growth stock; CHEK is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.